This document summarizes a presentation on patent valuation in the evolving intellectual property market. It discusses the role of patent valuation across strategic planning, M&A, licensing, and litigation. It notes that most patent value is concentrated in a minority of patents and outlines approaches to identify core versus peripheral patents. The document then describes methods to establish patent values, including cost, investment value, and real options valuation which accounts for uncertainty. It provides an example valuation of a biotech patent using the real options approach and concludes with a case study applying real options to determine arms-length royalty rates.
Building an Effective IP Portfolio without Breaking the Bank - John Sadler, C...marcus evans Network
Building an Effective IP Portfolio without Breaking the Bank - Presentation by John Sadler, Vice President, R&D, Cervel Neurotech delivered at the marcus evans Medical Device R&D Summit June 2014, held in Las Vegas
Building an Effective IP Portfolio without Breaking the Bank - John Sadler, C...marcus evans Network
Building an Effective IP Portfolio without Breaking the Bank - Presentation by John Sadler, Vice President, R&D, Cervel Neurotech delivered at the marcus evans Medical Device R&D Summit June 2014, held in Las Vegas
Risk Factors as Building Blocks for Portfolio DiversificationCallan
Author: Eugene Podkaminer
Asset classes can be broken down into building blocks, or factors, that explain the majority of the assets’ risk and return characteristics. A factor-based investment approach enables the investor theoretically to remix the factors into portfolios that are better diversified and more efficient than traditional portfolios.
Seemingly diverse asset classes can have unexpectedly high correlations—a result of the significant overlap in their underlying common risk factor exposures. These high correlations caused many portfolios to exhibit poor diversification in the recent market downturn, and investors can use risk factors to view their portfolios and assess risk.
Although constructing ex ante optimized portfolios using risk factor inputs is possible, there are significant challenges to overcome, including the need for active, frequent rebalancing; creation of forward-looking assumptions; and the use of derivatives and short positions. However, key elements of factor-based methodologies can be integrated in multiple ways into traditional asset allocation structures to enhance portfolio construction, illuminate sources of risk, and inform manager structure.
You Need Defensive Patents but You Don't Have Any. Now What? A Case StudyErik Oliver
The setting is familiar: a large corporate asserter uses its patents against a smaller, high-growth company with no patents. Companies like Qualcomm, IBM, Nokia, and Microsoft regularly assert their patents. This case study describes how one of our clients included patent buying into their patent strategy to successfully defended against a corporate assertion by acquiring patents in the open market.
Speaker: Raphael Ronen, Commercialization Manager, The Innovations Group (TIG)
Within universities and research institutions there are no shortage of good ideas; but not all of those ideas make commercial sense. In this lecture, we explore what makes a technology worthwhile commercializing. We also touch on some of the lessons we can take from the university setting and apply to any start-up technology.
Part of the CIBC Presents Entrepreneurship 101 lecture series: http://www.marsdd.com/ent101
ICIC 2014 Valuing IP in the Chemical Space – Science, Art and Special Conside...Dr. Haxel Consult
The valuation of intellectual property is becoming an increasingly important component of realising return on R&D; investment, overall business strategy and IP portfolio management. Like other forms of property, the value of intellectual property is determined by what the buyer is prepared to pay for its perceived value, and what the seller is willing to accept. This is ultimately decided by negotiation. However, there is much that can be done to substantiate the value in support of the position of either the seller or the buyer. From the seller’s viewpoint, being able to place the IP accurately on the competitive landscape is critical to establishing how important the IP is, and hence its perceived market value. On the buyer’s side, the accurate assessment of the market position held by the IP on the technology landscape against competition will help determine whether this is a blocking technology, or whether it can ultimately be worked around. This is a combination of science and art. There are also special considerations to be factored in for the chemical technology space. In all cases, IP information and analysis tools play a central role in providing support for valuation of IP. This presentation will use a case study approach to examine the issues and provide insight into how organizations can more accurately assess the importance of their IP, and hence the current and potential market value of that IP.
Risk Factors as Building Blocks for Portfolio DiversificationCallan
Author: Eugene Podkaminer
Asset classes can be broken down into building blocks, or factors, that explain the majority of the assets’ risk and return characteristics. A factor-based investment approach enables the investor theoretically to remix the factors into portfolios that are better diversified and more efficient than traditional portfolios.
Seemingly diverse asset classes can have unexpectedly high correlations—a result of the significant overlap in their underlying common risk factor exposures. These high correlations caused many portfolios to exhibit poor diversification in the recent market downturn, and investors can use risk factors to view their portfolios and assess risk.
Although constructing ex ante optimized portfolios using risk factor inputs is possible, there are significant challenges to overcome, including the need for active, frequent rebalancing; creation of forward-looking assumptions; and the use of derivatives and short positions. However, key elements of factor-based methodologies can be integrated in multiple ways into traditional asset allocation structures to enhance portfolio construction, illuminate sources of risk, and inform manager structure.
You Need Defensive Patents but You Don't Have Any. Now What? A Case StudyErik Oliver
The setting is familiar: a large corporate asserter uses its patents against a smaller, high-growth company with no patents. Companies like Qualcomm, IBM, Nokia, and Microsoft regularly assert their patents. This case study describes how one of our clients included patent buying into their patent strategy to successfully defended against a corporate assertion by acquiring patents in the open market.
Speaker: Raphael Ronen, Commercialization Manager, The Innovations Group (TIG)
Within universities and research institutions there are no shortage of good ideas; but not all of those ideas make commercial sense. In this lecture, we explore what makes a technology worthwhile commercializing. We also touch on some of the lessons we can take from the university setting and apply to any start-up technology.
Part of the CIBC Presents Entrepreneurship 101 lecture series: http://www.marsdd.com/ent101
ICIC 2014 Valuing IP in the Chemical Space – Science, Art and Special Conside...Dr. Haxel Consult
The valuation of intellectual property is becoming an increasingly important component of realising return on R&D; investment, overall business strategy and IP portfolio management. Like other forms of property, the value of intellectual property is determined by what the buyer is prepared to pay for its perceived value, and what the seller is willing to accept. This is ultimately decided by negotiation. However, there is much that can be done to substantiate the value in support of the position of either the seller or the buyer. From the seller’s viewpoint, being able to place the IP accurately on the competitive landscape is critical to establishing how important the IP is, and hence its perceived market value. On the buyer’s side, the accurate assessment of the market position held by the IP on the technology landscape against competition will help determine whether this is a blocking technology, or whether it can ultimately be worked around. This is a combination of science and art. There are also special considerations to be factored in for the chemical technology space. In all cases, IP information and analysis tools play a central role in providing support for valuation of IP. This presentation will use a case study approach to examine the issues and provide insight into how organizations can more accurately assess the importance of their IP, and hence the current and potential market value of that IP.
Companies have more options than ever before as they decide between investing in the development of a certain technological capability internally, licensing-in technology, or buying a patent or patents to obtain the freedom to operate. We and several other panelists discuss what IP lawyers both in-house and at law firms should bring to the table in these discussions.
The Economics of Patent Litigation & Damages Brian BussBrian Buss
Presentation by Brian Buss of Nevium at the 2017 International Intellectual Property Law Association (IIPLA) Annual Meeting in Silicon Valley covering damages calculations in patent infringement litigation
Freedom to Operate in the Pharmaceutical SectorAdrian Bradley
This presentation covers the essential aspects of planning and executing a freedom to operate or patent clearance exercise in the pharmaceutical sector. It deals with the search phase, the analysis phase and the follow-up phase. It is relevant for in-house IP attorneys and development managers.
Discover the innovative and creative projects that highlight my journey throu...dylandmeas
Discover the innovative and creative projects that highlight my journey through Full Sail University. Below, you’ll find a collection of my work showcasing my skills and expertise in digital marketing, event planning, and media production.
Event Report - SAP Sapphire 2024 Orlando - lots of innovation and old challengesHolger Mueller
Holger Mueller of Constellation Research shares his key takeaways from SAP's Sapphire confernece, held in Orlando, June 3rd till 5th 2024, in the Orange Convention Center.
Buy Verified PayPal Account | Buy Google 5 Star Reviewsusawebmarket
Buy Verified PayPal Account
Looking to buy verified PayPal accounts? Discover 7 expert tips for safely purchasing a verified PayPal account in 2024. Ensure security and reliability for your transactions.
PayPal Services Features-
🟢 Email Access
🟢 Bank Added
🟢 Card Verified
🟢 Full SSN Provided
🟢 Phone Number Access
🟢 Driving License Copy
🟢 Fasted Delivery
Client Satisfaction is Our First priority. Our services is very appropriate to buy. We assume that the first-rate way to purchase our offerings is to order on the website. If you have any worry in our cooperation usually You can order us on Skype or Telegram.
24/7 Hours Reply/Please Contact
usawebmarketEmail: support@usawebmarket.com
Skype: usawebmarket
Telegram: @usawebmarket
WhatsApp: +1(218) 203-5951
USA WEB MARKET is the Best Verified PayPal, Payoneer, Cash App, Skrill, Neteller, Stripe Account and SEO, SMM Service provider.100%Satisfection granted.100% replacement Granted.
Kseniya Leshchenko: Shared development support service model as the way to ma...Lviv Startup Club
Kseniya Leshchenko: Shared development support service model as the way to make small projects with small budgets profitable for the company (UA)
Kyiv PMDay 2024 Summer
Website – www.pmday.org
Youtube – https://www.youtube.com/startuplviv
FB – https://www.facebook.com/pmdayconference
Top mailing list providers in the USA.pptxJeremyPeirce1
Discover the top mailing list providers in the USA, offering targeted lists, segmentation, and analytics to optimize your marketing campaigns and drive engagement.
The world of search engine optimization (SEO) is buzzing with discussions after Google confirmed that around 2,500 leaked internal documents related to its Search feature are indeed authentic. The revelation has sparked significant concerns within the SEO community. The leaked documents were initially reported by SEO experts Rand Fishkin and Mike King, igniting widespread analysis and discourse. For More Info:- https://news.arihantwebtech.com/search-disrupted-googles-leaked-documents-rock-the-seo-world/
3.0 Project 2_ Developing My Brand Identity Kit.pptxtanyjahb
A personal brand exploration presentation summarizes an individual's unique qualities and goals, covering strengths, values, passions, and target audience. It helps individuals understand what makes them stand out, their desired image, and how they aim to achieve it.
VAT Registration Outlined In UAE: Benefits and Requirementsuae taxgpt
Vat Registration is a legal obligation for businesses meeting the threshold requirement, helping companies avoid fines and ramifications. Contact now!
https://viralsocialtrends.com/vat-registration-outlined-in-uae/
Understanding User Needs and Satisfying ThemAggregage
https://www.productmanagementtoday.com/frs/26903918/understanding-user-needs-and-satisfying-them
We know we want to create products which our customers find to be valuable. Whether we label it as customer-centric or product-led depends on how long we've been doing product management. There are three challenges we face when doing this. The obvious challenge is figuring out what our users need; the non-obvious challenges are in creating a shared understanding of those needs and in sensing if what we're doing is meeting those needs.
In this webinar, we won't focus on the research methods for discovering user-needs. We will focus on synthesis of the needs we discover, communication and alignment tools, and how we operationalize addressing those needs.
Industry expert Scott Sehlhorst will:
• Introduce a taxonomy for user goals with real world examples
• Present the Onion Diagram, a tool for contextualizing task-level goals
• Illustrate how customer journey maps capture activity-level and task-level goals
• Demonstrate the best approach to selection and prioritization of user-goals to address
• Highlight the crucial benchmarks, observable changes, in ensuring fulfillment of customer needs
Digital Transformation and IT Strategy Toolkit and TemplatesAurelien Domont, MBA
This Digital Transformation and IT Strategy Toolkit was created by ex-McKinsey, Deloitte and BCG Management Consultants, after more than 5,000 hours of work. It is considered the world's best & most comprehensive Digital Transformation and IT Strategy Toolkit. It includes all the Frameworks, Best Practices & Templates required to successfully undertake the Digital Transformation of your organization and define a robust IT Strategy.
Editable Toolkit to help you reuse our content: 700 Powerpoint slides | 35 Excel sheets | 84 minutes of Video training
This PowerPoint presentation is only a small preview of our Toolkits. For more details, visit www.domontconsulting.com
Digital Transformation and IT Strategy Toolkit and Templates
Patent Values in the Evolving IP Market
1. Patent Values in the Evolving I.P.
Market
PLI Hot Topic Telebriefing
May 2, 2007
Fernando Torres, MSc
Chief Economist
ftorres@ipmetrics.net
2. Issues
1. Role of Patent Valuation1. Role of Patent Valuation
2. Identifying & Accounting for Value2. Identifying & Accounting for Value
3. Licensing Rates, pricing M&A’s3. Licensing Rates, pricing M&A’s
4. Values in Litigation4. Values in Litigation
3. Patent Value Statistics
•Patent value distributions are skewed; i.e. most of the value
is represented by a minority of patents:
5. Role of Patent Valuation
• Although patents values cannot be observed directly (unlike
stocks & bonds) and requires specialized analysis, the
contemporary role of patent valuation cuts across most
management functions:
• Strategic
• Key to deal valuation
• Throughout Strategic Planning and M&A process:
• Strategy
• Target Id
• Valuation
• Initial negotiation
• Due diligence
• Closing
• Financial Reporting
6. Issues identifying patent values
• Internally generated intangibles are expensed or (for
R&D) recorded at historical cost
• Balance sheet undervalues patents
• Acquired intangibles allocated at valuation date
• Balance sheet only reflects acquired patents
• Thus, not all patent values reflected in financials, and not
all patents disclosed may be core patents
• Still true in FASB No. 157
7. Identify patent bundles
for value
• Analyze quality of patent portfolio
• Relevance to current/future business
• Relative strength analysis
• Stratify IP / IA
• Core v. Periphery (not only technologically)
• Peripheral portfolios may be monetized
• Vertical and horizontal
• Out-licensing / Spin-off
• Potential infringement assessment
8. Qualitative Analysis of
IA/IP
• Forward/backward patent references
• Breadth of key claims
• Challenge/infringement record
• Associated trade secrets, knowledge bases, trademarks
9. Standards of Value
• Fair Market Value
• The price at which property would change hands
between a willing buyer and a willing seller when the
former is not under any compulsion to buy and the
latter is not under any compulsion to sell, both parties
having reasonable knowledge of relevant facts. (IRS.-
Hypothetical)
• Fair Value
• The amount at which an asset could be bought or sold
in a current transaction between willing parties, that is,
other than in a forced or liquidation sale. (FASB.-
Specific synergies)
10. Establish patent values
• Cost
• Investment value
• Reserve value
• Blocking value
• Monopoly value
• Value to licensor
• Value to (hypothetical) licensee
• Valuation of un-commercialized patents
11. Real Options Approach
• Adapted to patent valuation from the field of
financial analysis
• Draws on a parallel between patents and stock
options; the right, not obligation, during some
specified time, to purchase an underlying asset
whose price (value) is subject to some form of
random variation (uncertainty)
• A patent gives its owner the right to exclude others
from using the underlying invention, and further
investment is required to exploit its commercial
potential.
12. Real Options Valuation
• Both instruments have a direct and precise pricing relationship
with an underlying asset: a company in the case of stock
options, and an innovation in the case of a patent
• Either right can be transferred (license). The transfer price is
less than the full value of the underlying asset. The licensee,
in the case of patents, will only enter the transaction with the
expectation of reaping the difference between the full value of
the patent and the license price (paid-up or ongoing royalty)
• A significant difference, however, is that (until recently—
Ocean Tomo Auction) there are no organized markets for
patents and most intellectual property assets.
13. Real Option Valuation
• Key concept (Black-Scholes): the higher the volatility of
returns is, the higher the value of the patent and the
licensing rates
Net Payoff from
introducing
product
Net Payoff from
introducing
product
NPV
Cash Flows
NPV
Cash Flows
Cost of
Introduction
Cost of
Introduction
Patent
Value
Patent
Value
14. Illustration: Valuing a
Patent
• A bio-technology firm with a patent on a drug called Xenova,
which has FDA approval to treat multiple sclerosis.
• Estimates for use in the option pricing model:
• Potential market and expected price yields a PV of cash flows
of $ 3.4 billion (S)
• The initial cost of developing the drug for commercial use is
estimated to be $2.9 billion, if the drug is introduced today
(K)
• The patent expires in 17 years, and the current long-term
treasury bond rate is 6.0% and cost of delay is 1/17 (or 5.9%)
as all excess profit is assumed to vanish upon expiration.
• Average variance in firm value for publicly traded bio-
technology firms is 0.225
15. Illustration: Options
Formula
• Value of the patent: Se-dt
N(d1) - Ke-rt
N(d2)
• 3.4exp(-0.059)(17)(0.8720) –
2.9exp(-0.06)(17)(0.2076) = $0.9 billion
• The NPV of this project is only ½ billion:
• NPV = $3.4 - $ 2.9 million = $ 0.5 billion
• The firm can benefit from the flexibility of delaying
introduction until value of implemented patent equals
NPV of the project
16. Case Study
• A “nutraceutical” company developed and licensed-in a
number of patents involved in the formulation of their
flagship product.
• Goals: To form an IP holding company for the patents,
licenses, pending applications, and trademarks, which
will receive “arms-length” royalties in a lower-tax
jurisdiction
• Problem: what is the right rate to charge for the
technology bundle?
17. Real Options Approach to
Royalty Rates
• The B-S model can be adapted to yield royalty rates
(based on Denton & Heald)
• Given the risk and expiration of the patent these rates will
balance the risk-adjusted profit expectation of the
licensor and the licensee
Where:
RR is the Royalty Rate
PR is the Profit Ratio
N(∙) is the Normal Distribution
σ is the standard deviation
T is the life span of the patent
r is the Risk-free rate
Where:
RR is the Royalty Rate
PR is the Profit Ratio
N(∙) is the Normal Distribution
σ is the standard deviation
T is the life span of the patent
r is the Risk-free rate
)]
2
()
2
([
)
2
()
2
(
TNTNe
TNTN
PRRR
rT σσ
σσ
−−+
−−
×=
18. Case Study Conclusion
• In this case, the patents involved had relatively short lives
left, newer patents were about to become available, and
the industry has experienced relatively high volatility
• The rates the option-pricing model allowed us to
determine a royalty rate of 1.8% with a likely range of
plus or minus 0.4%
Editor's Notes
Good afternoon…For this section of the briefing there are four major topic areas I would like to cover:
No. 1 is the question of what patent values are and what role does a “patent valuation” appraisal play in your companies and/or your practices
No. 2 then drills down into the key step of actually identifying the patents from an analysis of a company’s public financial information
Third, I’ll touch on another critical component of a valuation analysis, and that is the determination of royalty rates, with particular attention to the due diligence surrounding business transactions involving patents, and finally…
In fourth place I’ll talk a little bit about the valuation of patents in a litigation environment
At first glance, it seems clear that everyone involved in business and patent law would have an intuitive understanding of what is meant by “patent value”. However, some may emphasize value from a technical perspective, others may be thinking of the validity and legal value of a patent, while financial folks will clearly be thinking about the economic value of a patent.
Technical value and legal value actually have very specific goals and, although they may be necessary components of an evaluation of a patent portfolio, are substantially subjective and not enough to be the basis of financial decision making.
The economic value of a patent, which is the sense of value we want to talk about today, is meant to be a somewhat objective value, the current value of the economic profit that a patent can generate during its statutory life span if put into practice commercially.
Obviously, if patent values where that simple, you wouldn’t have paid good money to listen today…right?
Let’s leave the nitty-gritty of how a patent’s economic value is calculated for later, and get a sense first of how much patents are typically worth. [Ray has already talked about the values reached in the recent auctions…but] in most, if not all, studies of patent values around the world, the most striking and common finding seems to be the fact that valuable patents are the minority, and that most are not worth very much.
For instance, around the turn of the century, the 21st century that is, a survey of patent value studies found that, in the USA and Germany (specifically) the top 10% of patents represented over 80% of the value. What’s more, For US universities in particular, the top 10% of institutions represented over 90% of patent values.
If we picture a bell-curve distribution, like the one teachers use to bump-up grades, patent values are really not distributed in a nice normal symmetric way, rather, their distribution is skewed to one side, so that most of the value is concentrated in a few very valuable patents, and tapers off toward most patents having lesser values.
A more recent study by the European Union in 2005 found that for Germany, Spain, France, Italy, the Netherlands, and the United Kingdom, the same concentration applies. In the UK for example, more than 50% (53%) of patents are worth less than 1 million Euros (just under $1.4 million USD), another 25% are worth between 1 and 3 million euro (1.4 – 4.2), and only 10% are worth more than 100 million Euros (136 milion dollars). This is all the more remarkable if you consider how much pharmaceutical R&D costs, billions, how many drugs don’t pan-out, and how important pharmaceutical patents are generally considered to be.
Now, patents are generally recognized as a business asset, and many characteristics of a patent are paralleled by other relatively intangible assets (like financial assets in particular promises-claims) , a big problem is that patent values cannot be observed directly, we can’t look them up on the wall street journal like stocks and bonds. It requires a specialized study. But, even if it can be easily observed, the value of a company's patent portfolio plays an important role is many decision making functions:
Strategy, where to invest in the future, what to acquire, what to spin off. Throughout the planning and m&a process, an idea of the value of what the company owns, what it can acquire, what it can sell in terms of businesses. Even outside of biotech, where patents are sometimes the only product of a company, how can one advise a company on how much to pay for an acquisition…not only do we have to do the due diligence to check on what the target actually owns, and how valid it may be,…in the end the deal is closed based on an amount of money. And after a transaction, there’s the financial reporting requirements, and with FASB 141, 142, 144 you don’t want to overestimate the value of patents that have been acquired based on what the seller though about them, and then deal with disclosing impairment charges.
SO…patent values play a central role in linking patenting activity into business strategy and transactions.
Now, on to the second topic area…identifying patents for valuation…
The first obstacle to determine the value of patents is the reality of GAAP: internally generated intangibles, like patents, are recorded as expenses (although there are special rules for R&D in process) and are not recorded as assets on the balance sheet. Even if we were to get all the expense related to a company’s patents, conventional accounting practice would only be recording their historical cost. A key economic principle is that historical cost is not economic value. You need to account for inflation, market changes, technical obsolescence, new applications, waste (excessive cost) to reflect the current value of the potential profit obtainable from the patent but, there’s more…Even if the patent is not practiced, it may well have a “blocking value” by keeping the competition from improving their products or methods....
The situation is, of course a little more complicated by the fact that, since at least 2001, acquired IP is now recorded at their allocated acquisition value, so company’s that grow by M&As have more itemized intangible value in their books, than company’s that develop their own technology.
So…no all of the value of patents is reflected or reported in company financials, and even when they are reported, they may still not be the core technologies of a company, nor implemented. (this is still going to be true once FASB 157 comes into effect at the end of this year). One of the most striking things about this is that, according to some studies the overwhelming majority of the S&P500’s market value has to be attributed to intangibles (trademarks & patents mainly), in other words the book-to-market multiples are historically very high, not because stocks are overvalued, but because intangibles are not recorded in the books!
What to do then, to identify patent values.
One step is to take time to analyze patent quality from an economic or financial perspective, to check which patents are actually relevant to the company’s current business, to the future strategy, and which support the company’s competitive position better. We typically have to segregate core and peripheral patents, to concentrate the valuation only on the core (the concentrated distribution is also present intra-company to some extent), and strategically, doing this also helps identify some patents that are non-core and can be monetized in some way (although this is a very difficult task).
There is, of course an economic and financial aspect to the potential infringement of a patent portfolio, as long as the company can afford to enforce its rights of course…
__________________________________
Anecdotes: C&A had car model by car model patents, very specific,…with limited use in a way because no one else would be manufacturing the same model/year and, contractually, if reassigned, the IP would travel with the contract to the new manufacturer. So only broader (eg, technique manufacturing processes) would have real economic value, or when coupled with trademarks (invisitec, acro-edge) etc.
Others, motorola, malden mills metro one
AS far as quality indicators, which have a role in defining patent value, its important to review references back/forth and their assignements as they are good indicators of the market place where the invention or method can sell and, therefore, where it can be valued.
Now before getting bogged down in details, a valuation has to have clearly defined the concept of value that is going to be used, what is usually called the “std of value”
There are many variations of standards but two stand out as central ones, what the IRS considers Fair market value, and what the FASB considers Fair Value.
= definitions= The first one is obviously a “hypothetical” value, and it emphasizes full information on both sides…this can be very important in M&As and it’s the basis for tax purposes of course…The FASB definition implies a specific transaction, and will consider the synergies of the acquired and existing patent portfolios, and this is the basis for financial reporting.
In a specific transaction however, buyer and seller may operate from a different point of view and knowledge about the patent, and value it very differently…
So…depending on the particular purpose of the analysis, the stage of the management process where it is used, and the destination of the result (CEO, IRS or SEC), the actual amount of value may reflect different considerations, building on cost, value if acquired, the value of reserving a technology for exclusive use, the value of blocking competitors, the value of first-to-market advantages, the value if licensed (actual license or opportunity cost). In any case, it is important that patents have economic value even if not in commercial use.
All of the preceding considerations boil down to possibility of applying conventional asset-valuation methods cost / market / income which use a discounted cash flow approach to value. But, it’s important to recognize that there are many situations when those conventional methods may not be sufficient, particularly when:
It is not yet commercialized
When most of the investment expense has not happened, and is still being decided
When the litigation value is important, or strategic blocking
When the cost of maintaining the patents is a consideration (You don’t want to let a key patent lapse for “cost cutting”’s sake and then have a need for it…
The latest approach to those situations is to adapt the valuation of stock options to value patents. This approach seems to be more advanced in Europe than in the US, and there are opposing points of view about some key questions, but the general direction of valuation practice is that its use is more likely to be insightful than the traditional methods.
This approach treats a patent not strictly as a financial asset, but as an intellectual property right.
IN this approach, a key concept about patent values is this:…
Thus patent values can be expected to be higher in new technology industry segments, such as biotech, nanotech, and much less in stodgy traditional industries, which seems to underlie the valuation multiples of publicly traded companies in these industries, higher multiples for “growth” sticks, and lower ones for “value” companies.
Another conclusion in these new methodologies is that patents seldom are worthless, until they approach the end of their lives, there is still a probability that the NPV of the implementation/litigation will be higher than the NPV of the investment that is still needed…
In the downloadable materials I included some sample applications of this analysis, but here we just need to turn to two last areas to remark:
Setting royalty rates
Values in Litigation
RRates, what is new in this area is the possibility of applying the real options approach to determine the proper rates fro a transaction, or even for transfer pricing. Briefly, we can use the same approach to value a license balancing the probability that, if the rate is too high, the licensee and the license will fail, and if its too low the licensor loses a lot of value.
In litigation, the latest methods cannot be used, at least not until there is sufficient recognition of them. Valuation of patent infringement damages still maintains the use of the conventional discounted cash flow analysis, but sometimes the calculations of a reasonable royalty are greatly exaggerated, as in the recent Lucent Technologies et al. v. Gateway Inc. et al., (MP3 audio patent) decision of the district court for California’s southern district, which ordered Microsoft to pay $1.5 billion in damages based on a reasonable (sic) royalty of 0.5% of the value of the computers which had Windows installed! This is much more than those partial patents would reasonably be worth in the market ($1 to $3 milion) So a good valuation in litigation is worth, literally, billions !!!
Thanks